Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06344104
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-03-27
Brief Title:
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Double-Blind Randomised Placebo-Controlled Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BaxAsia
Brief Summary:
The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets
Detailed Description:
This is a Phase III multicentre randomised double-blinded placebo-controlled parallel group study to evaluate the safety tolerability and effect of 1 or 2 mg baxdrostat versus placebo administered QD orally on the reduction of SBP in approximately 300 participants aged 18 years with HTN 140 mmHg at Screening 135 mmHg at randomisation despite a stable regimen of 2 antihypertensive agents at baseline one of which is a diuretic uHTN or 3 antihypertensive agents at baseline one of which is a diuretic rHTN
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None